Tag: pulmonary drugs market forecast

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Pulmonary Drugs Market?

The market size of pulmonary drugs has seen a consistent rise in the past few years. Its growth is expected to march forward from $54.28 billion in 2024 to $56.98 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.0%. The significant growth witnessed in the historic period can be credited to the escalating incidence of respiratory diseases, a surge in smoking rates, an augmenting elderly population, wider accessibility to healthcare services, and rising pollution levels.

Expectations are high for the pulmonary drugs market as it’s predicted to experience robust growth in the coming years. The market is projected to increase to $70.35 billion by 2029, with a compound annual growth rate (CAGR) of 5.4%. The driving factors for this growth during the forecast period comprise of an enhanced healthcare infrastructure, an escalation in cardiovascular disease cases, the extension of homecare treatments, heightened awareness of pulmonary diseases, and a surge in asthma cases. The major trends to be seen during this forecast period encompassed technological evolution, the use of artificial intelligence in drug discovery, an increase in the use of smart inhalers, advancements in nanotechnology-based formulations, and progress in gene therapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What Underlying Factors Are Supporting The Pulmonary Drugs Market Growth?

The escalating frequency of disorders related to the respiratory system is predicted to drive the expansion of the pulmonary drugs market. These medical issues, which impact the lungs and breathing passages, hinder the usual capacity to breathe and exchange oxygen. Due to the increasing prominence of smoking habits, such disorders are on the rise, leading to harmful impacts on the lungs and chronic diseases. Pulmonary medication plays an integral part in managing these issues by enhancing lung operation, lowering inflammation, and easing obstruction in the airway for improved breathing. For instance, the Bureau of Labor Statistics, a government agency in the United States, noted in November 2023 that the rate of sickness among private industry employers increased from 37.7 cases in 2021 to 45.2 cases per 10,000 FTE employees in 2022. This increase was primarily due to a higher incidence of respiratory problems, which went up from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Hence, the escalating respiratory disorders are contributing to the growth of the pulmonary drugs market.

Which Sub-Segments Are Driving Growth Within The Pulmonary Drugs Market?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Future-Focused Trends Are Anticipated In The Pulmonary Drugs Market?

Focusing on the latest drug innovations such as Single-Inhaler Triple Therapy (SITT), prominent companies in the pulmonary drugs market aim to improve the effectiveness of treatments, increase patient compliance, and facilitate simpler medication schedules for improved disease management. SITT is an advanced treatment strategy that integrates three distinct medications into one inhaler for a more effective management of chronic respiratory ailments like Chronic Obstructive Pulmonary Disease (COPD). For example, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, a pharmaceutical firm based in India, rolled out India’s first SITT, Trelegy Ellipta, meant for patients with COPD. This treatment employs fluticasone furoate, umeclidinium, and vilanterol to better lung functionality and decrease symptom flare-ups. The forward-thinking Ellipta inhaler guarantees correct dosage and increases patient compliance when compared to multiple-inhaler therapies. This introduction seeks to streamline treatment and enhance patient results, given that over 100 million COPD patients exist in India.

Who Are The Dominant Players In The Pulmonary Drugs Market Today?

Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

How Do Regional Dynamics Influence The Pulmonary Drugs Market Performance?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Pulmonary Drugs Market Size Shifted, And What Is the Outlook Through 2034?

In the past few years, the size of the pulmonary drugs market has seen consistent growth. The market’s growth is anticipated to rise from $54.28 billion in 2024 to $56.98 billion in 2025, with a compound annual growth rate (CAGR) of 5.0%. The historical growth is due to increasing rates of respiratory diseases, higher smoking rates, a growing elderly population, broader access to healthcare, and escalating pollution levels.

The market size of pulmonary drugs is predicted to experience robust expansion in the upcoming years. The market is projected to increase to $70.35 billion by 2029, with a compound annual growth rate (CAGR) of 5.4%. The growth during the projected period is attributed to factors such as the enhancement of healthcare infrastructures, increasing instances of cardiovascular diseases, expanding treatments at home, greater understanding of lung diseases, and a surge in asthma prevalence. Significant trends in the predicted period consist of advancements in technology, the use of AI for drug discovery, the adoption of smart inhalers, formulations based on nanotechnology, and progressions in gene therapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What Are the Core Market Drivers Propelling Growth in the Pulmonary Drugs Industry?

The escalating incidence of respiratory conditions is anticipated to drive the growth of the pulmonary drugs market. Respiratory ailments are diseases that affect the lungs and airways, obstructing normal breathing and the exchange of oxygen. These conditions are becoming more prevalent due to the increasing rates of smoking, which causes lung damage and chronic illnesses. Pulmonary medications play a vital role in treating respiratory disorders by enhancing lung function, decreasing inflammation, and relieving airway blockage for improved breathing. For example, cited by the Bureau of Labor Statistics, a US government agency, in November 2023, the sickness rate among private-sector employers in 2022 surged to 45.2 cases per 10,000 Full-Time Equivalent (FTE) workers, a jump from 37.7 cases in 2021. This elevation is primarily attributed to a higher incidence of respiratory illnesses, which increased from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 in 2022. Hence, the expanding respiratory conditions are propelling the growth of the pulmonary drugs market.

How Is the Pulmonary Drugs Market Segmented?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Which Regions Are Driving the Next Phase of the Pulmonary Drugs Market Growth?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Pulmonary Drugs Industry?

Leading firms in the pulmonary drugs market are increasingly focusing on developing innovative treatment methods like the single-inhaler triple therapy (SITT) to boost treatment effectiveness, promote patient compliance, and simplify medication regimens for improved disease control. SITT combines three separate medications into one inhaler to efficiently manage [chronic respiratory illnesses](https://www.wellmark.com/employer-news/chronic-respiratory-diseases-costly-conveniently-preventable) like chronic obstructive pulmonary disease (COPD). For instance, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, a pharmaceutical company based in India, introduced Trelegy Ellipta, marking India’s first SITT for patients struggling with COPD. This therapy merges fluticasone furoate, umeclidinium, and vilanterol, aiming to enhance lung efficiency and curb symptom exacerbations. The revolutionary Ellipta inhaler promises accurate dosing and promotes better patient compliance compared to therapies with multiple inhalers. This introduction aims to simplify treatment and enhance patient outcomes, considering the over 100 million COPD patients in India.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

How Is the Pulmonary Drugs Market Defined and What Are Its Core Parameters?

Pulmonary drugs refer to medications that target the respiratory system to improve lung function, reduce inflammation, and manage airway disorders. They are used for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23489

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pulmonary Drugs Market Grown from 2024 to 2025?

The market size for pulmonary drugs has seen considerable growth in the recent past. It is projected to escalate from $54.28 billion in 2024 to $57.53 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.0%. The growth during the historical period is a result of the increased prevalence of respiratory disorders, a rise in the rates of smoking, a swelling geriatric population, expanding access to healthcare, and a significant increase in pollution levels.

What Growth Rate Is Anticipated for the Pulmonary Drugs Market in the Coming Years?

In the upcoming years, the market size for pulmonary drugs is projected to witness robust growth, increasing to $71.91 billion by 2029 with a compound annual growth rate (CAGR) of 5.7%. This expansion during the forecast period is due to numerous factors such as the improvement of healthcare infrastructure, an increase in cardiovascular diseases, the growth of homecare treatments, heightened understanding of pulmonary diseases, and a surge in asthma cases. Key trends for the forecast period encompass technological innovation, the application of artificial intelligence in drug discovery, the usage of smart inhalers, the introduction of nanotechnology in drug formulation, and progress in gene therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Who Are the Leading Companies in the Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

What Are the Key Drivers of the Pulmonary Drugs Market?

The escalating occurrence of respiratory afflictions is anticipated to stimulate the expansion of the pulmonary drugs market in the future. Respiratory ailments involve medical issues that impact the lungs and airways, hindering regular breathing and the exchange of oxygen. The amplification of respiratory diseases is due to the increasing rate of smoking, which results in lung damage and chronic illnesses. Pulmonary medications are essential in managing respiratory ailments by enhancing lung performance, diminishing inflammation, and easing airway blockage for improved respiration. For example, the Bureau of Labor Statistics, a governmental agency in the US, reported in November 2023 that the disease rate amongst private sector employers in 2022 jumped to 45.2 cases per 10,000 FTE workers from 37.7 cases in 2021. This surge is primarily credited to the higher prevalence of respiratory diseases, which leaped from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Consequently, the escalating respiratory ailments are fueling the expansion of the pulmonary drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

What Are the Key Market Segments in the Pulmonary Drugs Industry?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Are the Latest Trends in the Pulmonary Drugs Market?

Pulmonary drugs market giants are concentrating their efforts on devising innovative treatments, such as single-inhaler triple therapy (SITT), with the goal of amplifying treatment effectiveness, endorsing patient compliance, and streamlining medication regimens for superior disease management. SITT is a multifaceted treatment method, combining three different drugs into one inhaler to support the management of chronic respiratory ailments like chronic obstructive pulmonary disease (COPD). For example, in April 2022, Trelegy Ellipta was introduced by GlaxoSmithKline Pharmaceuticals Limited, an Indian pharmaceutical firm, marking a first for India in single-inhaler triple therapy (SITT) for patients with COPD. The introduction of this therapy, which fuses fluticasone furoate, umeclidinium, and vilanterol, aims to augment lung function and diminish symptom flare-ups. The advanced Ellipta inhaler guarantees precise dosing and promotes patient consistency in comparison to therapies involving multiple inhalers. This new development is geared towards simplifying treatment procedures and enhancing patient health outcomes, marking a significant step considering India is home to more than 100 million COPD patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

What Are the Key Regional Markets in the Pulmonary Drugs Industry?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23489

This Report Delivers Insight On:

1. How big is the pulmonary drugs market, and how is it changing globally?

2. Who are the major companies in the pulmonary drugs market, and how are they performing?

3. What are the key opportunities and risks in the pulmonary drugs market right now?

4. Which products or customer segments are growing the most in the pulmonary drugs market?

5. What factors are helping or slowing down the growth of the pulmonary drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pulmonary Drugs Market Grown from 2024 to 2025?

The market size for pulmonary drugs has seen considerable growth in the recent past. It is projected to escalate from $54.28 billion in 2024 to $57.53 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.0%. The growth during the historical period is a result of the increased prevalence of respiratory disorders, a rise in the rates of smoking, a swelling geriatric population, expanding access to healthcare, and a significant increase in pollution levels.

What Growth Rate Is Anticipated for the Pulmonary Drugs Market in the Coming Years?

In the upcoming years, the market size for pulmonary drugs is projected to witness robust growth, increasing to $71.91 billion by 2029 with a compound annual growth rate (CAGR) of 5.7%. This expansion during the forecast period is due to numerous factors such as the improvement of healthcare infrastructure, an increase in cardiovascular diseases, the growth of homecare treatments, heightened understanding of pulmonary diseases, and a surge in asthma cases. Key trends for the forecast period encompass technological innovation, the application of artificial intelligence in drug discovery, the usage of smart inhalers, the introduction of nanotechnology in drug formulation, and progress in gene therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Who Are the Leading Companies in the Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

What Are the Key Drivers of the Pulmonary Drugs Market?

The escalating occurrence of respiratory afflictions is anticipated to stimulate the expansion of the pulmonary drugs market in the future. Respiratory ailments involve medical issues that impact the lungs and airways, hindering regular breathing and the exchange of oxygen. The amplification of respiratory diseases is due to the increasing rate of smoking, which results in lung damage and chronic illnesses. Pulmonary medications are essential in managing respiratory ailments by enhancing lung performance, diminishing inflammation, and easing airway blockage for improved respiration. For example, the Bureau of Labor Statistics, a governmental agency in the US, reported in November 2023 that the disease rate amongst private sector employers in 2022 jumped to 45.2 cases per 10,000 FTE workers from 37.7 cases in 2021. This surge is primarily credited to the higher prevalence of respiratory diseases, which leaped from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Consequently, the escalating respiratory ailments are fueling the expansion of the pulmonary drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

What Are the Key Market Segments in the Pulmonary Drugs Industry?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Are the Latest Trends in the Pulmonary Drugs Market?

Pulmonary drugs market giants are concentrating their efforts on devising innovative treatments, such as single-inhaler triple therapy (SITT), with the goal of amplifying treatment effectiveness, endorsing patient compliance, and streamlining medication regimens for superior disease management. SITT is a multifaceted treatment method, combining three different drugs into one inhaler to support the management of chronic respiratory ailments like chronic obstructive pulmonary disease (COPD). For example, in April 2022, Trelegy Ellipta was introduced by GlaxoSmithKline Pharmaceuticals Limited, an Indian pharmaceutical firm, marking a first for India in single-inhaler triple therapy (SITT) for patients with COPD. The introduction of this therapy, which fuses fluticasone furoate, umeclidinium, and vilanterol, aims to augment lung function and diminish symptom flare-ups. The advanced Ellipta inhaler guarantees precise dosing and promotes patient consistency in comparison to therapies involving multiple inhalers. This new development is geared towards simplifying treatment procedures and enhancing patient health outcomes, marking a significant step considering India is home to more than 100 million COPD patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

What Are the Key Regional Markets in the Pulmonary Drugs Industry?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23489

This Report Delivers Insight On:

1. How big is the pulmonary drugs market, and how is it changing globally?

2. Who are the major companies in the pulmonary drugs market, and how are they performing?

3. What are the key opportunities and risks in the pulmonary drugs market right now?

4. Which products or customer segments are growing the most in the pulmonary drugs market?

5. What factors are helping or slowing down the growth of the pulmonary drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pulmonary Drugs Market Grown from 2024 to 2025?

The market size for pulmonary drugs has seen considerable growth in the recent past. It is projected to escalate from $54.28 billion in 2024 to $57.53 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.0%. The growth during the historical period is a result of the increased prevalence of respiratory disorders, a rise in the rates of smoking, a swelling geriatric population, expanding access to healthcare, and a significant increase in pollution levels.

What Growth Rate Is Anticipated for the Pulmonary Drugs Market in the Coming Years?

In the upcoming years, the market size for pulmonary drugs is projected to witness robust growth, increasing to $71.91 billion by 2029 with a compound annual growth rate (CAGR) of 5.7%. This expansion during the forecast period is due to numerous factors such as the improvement of healthcare infrastructure, an increase in cardiovascular diseases, the growth of homecare treatments, heightened understanding of pulmonary diseases, and a surge in asthma cases. Key trends for the forecast period encompass technological innovation, the application of artificial intelligence in drug discovery, the usage of smart inhalers, the introduction of nanotechnology in drug formulation, and progress in gene therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Who Are the Leading Companies in the Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

What Are the Key Drivers of the Pulmonary Drugs Market?

The escalating occurrence of respiratory afflictions is anticipated to stimulate the expansion of the pulmonary drugs market in the future. Respiratory ailments involve medical issues that impact the lungs and airways, hindering regular breathing and the exchange of oxygen. The amplification of respiratory diseases is due to the increasing rate of smoking, which results in lung damage and chronic illnesses. Pulmonary medications are essential in managing respiratory ailments by enhancing lung performance, diminishing inflammation, and easing airway blockage for improved respiration. For example, the Bureau of Labor Statistics, a governmental agency in the US, reported in November 2023 that the disease rate amongst private sector employers in 2022 jumped to 45.2 cases per 10,000 FTE workers from 37.7 cases in 2021. This surge is primarily credited to the higher prevalence of respiratory diseases, which leaped from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Consequently, the escalating respiratory ailments are fueling the expansion of the pulmonary drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

What Are the Key Market Segments in the Pulmonary Drugs Industry?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Are the Latest Trends in the Pulmonary Drugs Market?

Pulmonary drugs market giants are concentrating their efforts on devising innovative treatments, such as single-inhaler triple therapy (SITT), with the goal of amplifying treatment effectiveness, endorsing patient compliance, and streamlining medication regimens for superior disease management. SITT is a multifaceted treatment method, combining three different drugs into one inhaler to support the management of chronic respiratory ailments like chronic obstructive pulmonary disease (COPD). For example, in April 2022, Trelegy Ellipta was introduced by GlaxoSmithKline Pharmaceuticals Limited, an Indian pharmaceutical firm, marking a first for India in single-inhaler triple therapy (SITT) for patients with COPD. The introduction of this therapy, which fuses fluticasone furoate, umeclidinium, and vilanterol, aims to augment lung function and diminish symptom flare-ups. The advanced Ellipta inhaler guarantees precise dosing and promotes patient consistency in comparison to therapies involving multiple inhalers. This new development is geared towards simplifying treatment procedures and enhancing patient health outcomes, marking a significant step considering India is home to more than 100 million COPD patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

What Are the Key Regional Markets in the Pulmonary Drugs Industry?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23489

This Report Delivers Insight On:

1. How big is the pulmonary drugs market, and how is it changing globally?

2. Who are the major companies in the pulmonary drugs market, and how are they performing?

3. What are the key opportunities and risks in the pulmonary drugs market right now?

4. Which products or customer segments are growing the most in the pulmonary drugs market?

5. What factors are helping or slowing down the growth of the pulmonary drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!

What Are the Projected Market Size and Growth Rates for the Pulmonary Drugs Market From 2025 To 2029?

The market size for pulmonary drugs has seen significant growth in the past few years. The market, valued at $54.28 billion in 2024, is predicted to increase to $57.53 billion in 2025, indicative of a compound annual growth rate (CAGR) of 6.0%. This notable increase during the historical period can be tied to several factors such as the increased occurrence of respiratory diseases, the escalation in smoking rates, a growing elderly population, wider healthcare availability, and a spike in pollution levels.

In the upcoming years, the size of the pulmonary drugs market is projected to experience robust growth, escalating to $71.91 billion by 2029 with a compound annual growth rate (CAGR) of 5.7%. The expansion within the forecast period is likely due to the advancement of healthcare facilities, the increased incidence of cardiovascular diseases, the augmentation of homecare therapies, the growing consciousness about lung diseases, and the prominence of asthma. Foreseen trends for the period include progress in technology, drug discovery facilitated by AI, utilization of smart inhalers, formulation based on nanotechnology, and progress in gene therapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What are the Fundamental Drivers and Innovations Shaping the Pulmonary Drugs Market?

The escalating incidence of respiratory conditions is likely to stimulate the expansion of the pulmonary drugs market in the future. Respiratory disorders, which impact the lungs and airways, disrupt usual breathing and the exchange of oxygen. The rise in such disorders is a result of increased smoking, which contributes to lung damage and chronic illnesses. Pulmonary medications are essential in controlling these disorders by enhancing lung performance, mitigating inflammation, and alleviating blocked airways for improved respiration. For example, the Bureau of Labor Statistics, a governmental agency in the United States, reported that the disease rate among private industry employers amplified to 45.2 cases per 10,000 FTE employees in 2022, a surge from 37.7 cases in 2021. This increase was primarily due to a heightened frequency of respiratory ailments, which expanded from 27.8 cases per 10,000 FTE employees in 2021 to 35.8 cases the following year. Thus, the proliferation of respiratory diseases is fuelling the growth of the pulmonary drugs market.

How Is the Pulmonary Drugs Market Segmented?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Which Regions Are Driving the Next Phase of the Pulmonary Drugs Market Growth?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Pulmonary Drugs Market?

Leading firms in the pulmonary drugs market are concentrating on the creation of novel therapies like single-inhaler triple therapy (SITT) to boost treatment effectiveness, augment patient compliance, and make medication schedules easier for superior disease control. The SITT treatment amalgamates three varied medicines in one inhaler to deal with chronic respiratory illnesses, for example, chronic obstructive pulmonary disease (COPD), more efficiently. For example, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, a pharmaceutical firm based in India, released Trelegy Ellipta, the first of its kind single-inhaler triple therapy (SITT) in India for COPD patients. This therapeutic approach merges fluticasone furoate, umeclidinium, and vilanterol to enhance pulmonary functionality and diminish symptom flare-ups. The advanced Ellipta inhaler guarantees accurate dosage and boosts patient adherence compared to numerous inhaler therapies. Given that India has over 100 million COPD patients, this introduction aims to streamline therapy and enhance patient results.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

How Is the Pulmonary Drugs Market Defined and What Are Its Core Parameters?

Pulmonary drugs refer to medications that target the respiratory system to improve lung function, reduce inflammation, and manage airway disorders. They are used for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23489

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model